Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.11 USD
Change Today 0.00 / 0.00%
Volume 0.0
BZYR On Other Exchanges
As of 8:10 PM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

burzynski research institute (BZYR) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/30/14 - $0.50
52 Week Low
06/19/14 - $0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

burzynski research institute (BZYR) Related Businessweek News

No Related Businessweek News Found

burzynski research institute (BZYR) Details

Burzynski Research Institute, Inc. operates a research and development facility of Antineoplaston drugs being tested for use in the treatment of cancer. The company focuses on the research, development, production, marketing, promotion, and sale of medical chemical compounds, such as growth-inhibiting peptides, amino acid derivatives, and organic acids. It is conducting Phase II clinical trial of Antineoplaston drugs. The company also provides consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.

2 Employees
Last Reported Date: 05/30/14
Founded in 1977

burzynski research institute (BZYR) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: --
Secretary and Treasurer
Total Annual Compensation: --
Vice President of Clinical Trials
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

burzynski research institute (BZYR) Key Developments

Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Newly-Diagnosed Anaplastic Astrocytoma

Burzynski Research Institute, Inc. announced the publication of data by the Burzynski Clinic on two of the company’s clinical stage products Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives. The phase II, single-arm, two-stage, interventional trial was conducted in the United States and evaluated adults with newly-diagnosed anaplastic astrocytoma (AA). The study was closed for admission after enrollment of 19 adults out of a planned 40 patients, as the goal for complete response had been met in four study eligible patients. Progression-free survival (PFS) and overall survival (OS) at 1, 2, 3, 5 and 10 years are presented. A small number of patients experienced serious, but reversible Grade 3 and 4 toxicities, including hypernatremia, hypokalemia and somnolence. No chronic toxicities were noted.

Burzynski Research Institute, Inc. Announces Publication of Phase 2 Clinical Study in Metastatic Colon Adenocarcinoma of the Liver

The Burzynski Research Institute, Inc. (BRI) announced that results of a study independently conducted by the Department of Surgery at Kurume University Medical Center in Japan have been published. The study, a randomized non-blinded phase 2 trial, compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections for colorectal metastasis of the liver. A total of 65 patients, with histologically confirmed metastatic colon adenocarcinoma of the liver, were evaluated. Primary endpoints included cancer-specific survival. Secondary endpoints included relapse-free survival, clinical status and extent of recurrence, salvage surgery rate and toxicity. BRI believed that the completion of the study represents an important milestone in the development of Antineoplastons and that further efficacy trials of Antineoplastons in colorectal cancer should continue to be pursued.

Burzynski Research Institute, Inc. Announces FDA Permission to Launch New Clinical Trial in Diffuse Intrinsic Brainstem Glioma

Burzynski Research Institute, Inc. announced that the U.S. Food and Drug Administration (FDA) has given the company permission to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). Study subjects will be placed in one of five treatment groups based on their age and whether or not they have received prior treatment for DIPG. The primary study endpoint is a decrease in the size of the tumor, either a partial response (>= 50% decrease in the size of the tumor) or a complete response (disappearance of the tumor). The study is in its final organizational stage and will begin accruing patients as soon as this organizational stage is completed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BZYR:US $0.11 USD 0.00

BZYR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BZYR.
View Industry Companies

Industry Analysis


Industry Average

Valuation BZYR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BURZYNSKI RESEARCH INSTITUTE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at